

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA vutrisiran for treating hereditary transthyretin-related
amyloidosis**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when no draft guidance was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
Yes. The following issues were identified: <ul style="list-style-type: none">• Comments about prevalence of the disease. The prevalence of a disease cannot be addressed by committee. The recommendation is within the full MA so is not restricted to any particular group.• Comments about the convenient mode of delivery impacting disabled people and those in remote area. The recommendation is positive so there is no action needed on this point.
2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

No. Equality issue is not relevant with a positive recommendation.

Approved by Associate Director (name): Jasdeep Hayre

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of vutrisiran for treating hereditary transthyretin-related amyloidosis

Issue date: January 2023

Date: 16 December 2022